NewAmsterdam Pharma Company N.V. (NAMS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

NewAmsterdam Pharma Company N.V. (NAMS) Healthcare & Pipeline Overview

NewAmsterdam Pharma, a clinical-stage biopharmaceutical firm, pioneers treatments for metabolic diseases, focusing on its lead candidate, obicetrapib, a CETP inhibitor designed to lower LDL-C and raise HDL-C. With a lean team and a Netherlands-based headquarters, the company targets a significant unmet need in cardiovascular health.

What Is the Investment Thesis for NAMS?

NewAmsterdam Pharma presents a notable research candidate based on the potential of obicetrapib to revolutionize cholesterol management. The drug's unique mechanism of action, simultaneously lowering LDL-C and raising HDL-C, addresses a significant unmet need in patients inadequately treated with statins. Positive Phase 3 trial results, expected in late 2026, could drive significant stock appreciation. With a market capitalization of $2.60B, the company's valuation hinges on successful clinical outcomes and subsequent commercialization. The ongoing clinical trials represent a key catalyst, while potential regulatory hurdles and competition from existing therapies pose risks. The company's high gross margin of 97.5% suggests strong future profitability if obicetrapib gains market acceptance.

Based on FMP financials and quantitative analysis

NAMS Key Highlights

Lead candidate obicetrapib targets CETP, reducing LDL-C and increasing HDL-C, offering a novel approach to cholesterol management.

• Currently in Phase 3 clinical trials, with results expected in late 2026, representing a critical milestone for potential regulatory approval.
• Gross margin of 97.5% indicates significant potential for profitability upon commercialization of obicetrapib.
• Market capitalization of $2.60B reflects investor confidence in the potential of obicetrapib and the company's pipeline.
• The company's lean structure, with 68 employees, allows for efficient operations and resource allocation.

Who Are NAMS's Competitors?

NAMS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NAMS's Key Strengths?

Novel CETP inhibitor mechanism of action.

• Promising Phase 3 clinical trial results to date.
• High gross margin potential.
• Experienced management team.

What Are NAMS's Weaknesses?

Reliance on a single lead candidate, obicetrapib.

• Limited commercialization experience.
• Negative profit margin.
• Relatively small employee base.

What Could Drive NAMS Stock Higher?

Release of Phase 3 clinical trial results for obicetrapib in late 2026.

• Potential regulatory approval of obicetrapib by the FDA and EMA.
• Enrollment and completion of ongoing clinical trials.
• Progress in securing strategic partnerships for commercialization.

What Are the Key Risks for NAMS?

Negative return on equity (-29.8%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Unfavorable clinical trial results.
• Regulatory delays or rejection.
• Competition from existing and emerging therapies.
• Patent expiration and generic entry.
• Dependence on successful development and commercialization of obicetrapib.

What Are the Growth Opportunities for NAMS?

• Growth opportunity 1: Successful completion of Phase 3 clinical trials for obicetrapib represents a major growth catalyst. Positive results would pave the way for regulatory approval and commercialization, potentially capturing a significant share of the cholesterol-lowering drug market. The global market for dyslipidemia treatments is projected to reach $30 billion by 2028, offering a substantial revenue opportunity for NewAmsterdam Pharma. The timeline for this growth opportunity is dependent on the trial outcomes, expected in late 2026, and subsequent regulatory review.
• Growth opportunity 2: Expansion into new indications beyond heterozygous familial hypercholesterolemia (HeFH) could further drive growth. Obicetrapib's mechanism of action may be applicable to other cardiovascular conditions, such as mixed dyslipidemia and atherosclerotic cardiovascular disease (ASCVD). Exploring these additional indications through clinical trials could broaden the target patient population and increase market potential. This expansion strategy could unfold over the next 3-5 years, contingent on clinical data and regulatory pathways.
• Growth opportunity 3: Strategic partnerships with established pharmaceutical companies could accelerate commercialization and expand market reach. Collaborating with a larger company with an existing sales force and distribution network would facilitate the launch of obicetrapib in key markets worldwide. This partnership could involve licensing agreements, co-promotion arrangements, or joint ventures. The timeline for securing such a partnership is uncertain but could materialize within the next 1-2 years following positive Phase 3 results.
• Growth opportunity 4: Development of a combination therapy with obicetrapib and other lipid-lowering agents could enhance efficacy and address unmet needs in specific patient populations. Combining obicetrapib with a statin or another novel therapy could provide a more comprehensive approach to cholesterol management. This strategy could differentiate NewAmsterdam Pharma from competitors and strengthen its market position. The development and clinical testing of a combination therapy would likely take 3-5 years.
• Growth opportunity 5: Geographic expansion into emerging markets, such as China and India, represents a significant growth opportunity. These markets have a large and growing population with increasing rates of cardiovascular disease. Adapting the commercialization strategy to meet the specific needs of these markets, including regulatory requirements and pricing considerations, would be crucial for success. This expansion could begin within 2-3 years following initial commercialization in developed markets.

What Are NAMS's Competitive Advantages?

• Proprietary CETP inhibitor technology.
• Strong intellectual property protection for obicetrapib.
• Positive clinical trial data demonstrating efficacy and safety.
• Experienced management team with expertise in drug development.

What Does NAMS Do?

Founded in 2019 and based in Naarden, the Netherlands, NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company dedicated to enhancing patient care for individuals suffering from metabolic diseases. The company's primary focus is the development and commercialization of obicetrapib, a novel, selective Cholesteryl Ester Transfer Protein (CETP) inhibitor. Obicetrapib has demonstrated in clinical trials the ability to significantly reduce low-density lipoprotein cholesterol (LDL-C) levels, often referred to as 'bad' cholesterol, while simultaneously increasing high-density lipoprotein cholesterol (HDL-C) levels, known as 'good' cholesterol. This dual-action mechanism sets obicetrapib apart from other cholesterol-lowering therapies. NewAmsterdam Pharma is strategically positioned to address the growing global burden of cardiovascular disease, a leading cause of mortality worldwide. By targeting CETP, obicetrapib offers a potentially more effective approach to managing cholesterol levels compared to traditional statin therapies, particularly for patients who do not achieve adequate LDL-C reduction with statins or who are intolerant to statins. The company is currently conducting Phase 3 clinical trials to evaluate the safety and efficacy of obicetrapib in various patient populations, including those with heterozygous familial hypercholesterolemia (HeFH) and those at high risk for cardiovascular events. The company operates with a relatively small team of 68 employees, allowing for streamlined decision-making and efficient resource allocation. NewAmsterdam Pharma's leadership team comprises experienced pharmaceutical executives with a proven track record in drug development and commercialization. The company's strategic focus on obicetrapib and its commitment to clinical research underscore its mission to transform the treatment landscape for metabolic diseases and improve patient outcomes.

What Products and Services Does NAMS Offer?

• Develop novel therapies for metabolic diseases.
• Focus on improving patient care in populations with high unmet needs.
• Lead investigational candidate is obicetrapib, a CETP inhibitor.
• Obicetrapib reduces LDL-C and increases HDL-C.
• Conduct Phase 3 clinical trials to evaluate obicetrapib's safety and efficacy.
• Target patients with heterozygous familial hypercholesterolemia (HeFH).
• Aim to address the limitations of existing statin therapies.

How Does NAMS Make Money?

• Develop and commercialize pharmaceutical products.
• Focus on licensing or partnering with larger pharmaceutical companies for distribution.
• Generate revenue through sales of prescription medications.
• Invest in research and development to expand product pipeline.

What Industry Does NAMS Operate In?

NewAmsterdam Pharma operates within the dynamic biotechnology sector, focusing on cardiovascular disease, a leading cause of death globally. The market for cholesterol-lowering drugs is substantial, with statins being the current standard of care. However, many patients do not achieve adequate LDL-C reduction with statins alone, creating a significant opportunity for novel therapies like obicetrapib. Competition includes established pharmaceutical companies and other biotech firms developing innovative approaches to lipid management. The industry is driven by an aging population, increasing prevalence of metabolic disorders, and advancements in drug development technologies.

Who Are NAMS's Key Customers?

• Patients with metabolic diseases, particularly high cholesterol.
• Physicians who prescribe lipid-lowering medications.
• Hospitals and clinics that treat cardiovascular conditions.
• Pharmacies that dispense prescription drugs.

NewAmsterdam Pharma Company N.V. Financial Trajectory

NewAmsterdam Pharma Company N.V. (NAMS) reported $3.7M in revenue for Q2 FY2026, reflecting 21.7% growth compared to the prior quarter. The company recorded a net loss of $64.1M, with diluted EPS of $-0.52. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, NAMS averaged $-0.54 in diluted EPS.

Company Profile

NewAmsterdam Pharma Company N.V. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Naarden, NL. The company is led by CEO Michael Harvey Davidson Facp.. NAMS has traded publicly since 2021.

How NewAmsterdam Pharma Company N.V. Is Valued

NewAmsterdam Pharma Company N.V. carries a market capitalization of $2.60B, placing it in the mid-cap category. Analyst price targets span from $45.00 to $58.00, with a consensus of $51.33. At the current price of $22.26, that implies approximately 131% upside potential. Relative to its peer group, NAMS's quantitative score of 21/100 is below the peer average of 79/100.

Return on equity for NewAmsterdam Pharma Company N.V. stands at -29.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -29.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.0%, the inverse of the P/E and a quick read on earnings relative to price.

NewAmsterdam Pharma Company N.V.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 19.07 places it in the safe zone, indicating low near-term bankruptcy risk.

NewAmsterdam Pharma Company N.V. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 9.2% below estimates on average.

Over the past six months, NewAmsterdam Pharma Company N.V. insiders filed 24 SEC Form 4 transactions — 15 sales and 9 purchases. On net that is roughly 319K shares disposed (about $9.8M), a signal worth weighing alongside the fundamentals.

NAMS Financials

NAMS Latest News

NAMS Analyst Consensus

NAMS MoonshotScore

What Investors Ask About NewAmsterdam Pharma Company N.V. (NAMS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources